149 related articles for article (PubMed ID: 1338309)
1. Synthesis and antitumour activities of quinolone antineoplastic agents.
Chu DT; Hallas R; Clement JJ; Alder J; McDonald E; Plattner JJ
Drugs Exp Clin Res; 1992; 18(7):275-82. PubMed ID: 1338309
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and antitumour activities of tetracyclic quinolone antineoplastic agents.
Chu DT; Hallas R; Tanaka SK; Alder J; Balli D; Plattner JJ
Drugs Exp Clin Res; 1994; 20(5):177-83. PubMed ID: 7875053
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of modified quinolones as antitumoral acridones.
Tabarrini O; Cecchetti V; Fravolini A; Nocentini G; Barzi A; Sabatini S; Miao H; Sissi C
J Med Chem; 1999 Jun; 42(12):2136-44. PubMed ID: 10377219
[TBL] [Abstract][Full Text] [Related]
4. Functionalized N(2-oxyiminoethyl) piperazinyl quinolones as new cytotoxic agents.
Rajabalian S; Foroumadi A; Shafiee A; Emami S
J Pharm Pharm Sci; 2007; 10(2):153-8. PubMed ID: 17706174
[TBL] [Abstract][Full Text] [Related]
5. Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity.
Yamashita Y; Ashizawa T; Morimoto M; Hosomi J; Nakano H
Cancer Res; 1992 May; 52(10):2818-22. PubMed ID: 1316228
[TBL] [Abstract][Full Text] [Related]
6. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
7. Biological characterization of a novel antitumor quinolone.
Clement JJ; Burres N; Jarvis K; Chu DT; Swiniarski J; Alder J
Cancer Res; 1995 Feb; 55(4):830-5. PubMed ID: 7850797
[TBL] [Abstract][Full Text] [Related]
8. Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model.
Zeng Q; Kwok Y; Kerwin SM; Mangold G; Hurley LH
J Med Chem; 1998 Oct; 41(22):4273-8. PubMed ID: 9784102
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with contrasting dual mechanisms of action against topoisomerase II and G-quadruplexes.
Kim MY; Duan W; Gleason-Guzman M; Hurley LH
J Med Chem; 2003 Feb; 46(4):571-83. PubMed ID: 12570378
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic quinolines (Part 3). Synthesis of 1-azolylalkyl-4(1H)-quinolones as cytotoxic agents.
Abel MD; Micetich RG; Nukatsuka M; Oreski AB; Tempest ML; Daneshtalab M
Drug Des Discov; 1996 Oct; 14(2):115-27. PubMed ID: 9010618
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and evaluation of psorospermin/quinobenzoxazine hybrids as structurally novel antitumor agents.
Kim MY; Na Y; Vankayalapati H; Gleason-Guzman M; Hurley LH
J Med Chem; 2003 Jul; 46(14):2958-72. PubMed ID: 12825936
[TBL] [Abstract][Full Text] [Related]
12. The quinobenzoxazines: relationship between DNA binding and biological activity.
Kwok Y; Sun D; Clement JJ; Hurley LH
Anticancer Drug Des; 1999 Oct; 14(5):443-50. PubMed ID: 10766299
[TBL] [Abstract][Full Text] [Related]
13. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH
J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485
[TBL] [Abstract][Full Text] [Related]
14. Novel antitumor indenoindole derivatives targeting DNA and topoisomerase II.
Bal C; Baldeyrou B; Moz F; Lansiaux A; Colson P; Kraus-Berthier L; Léonce S; Pierré A; Boussard MF; Rousseau A; Wierzbicki M; Bailly C
Biochem Pharmacol; 2004 Nov; 68(10):1911-22. PubMed ID: 15476662
[TBL] [Abstract][Full Text] [Related]
15. Potent antitumor activity of quinolone compounds with an unsaturated aminoazabicyclo group at the C-7 position of the quinolone ring.
Arakawa H; Mano E; Hakoda N; Yoshinari T; Nakagawa S; Okura A
Anticancer Drug Des; 1996 Apr; 11(3):221-9. PubMed ID: 8663909
[TBL] [Abstract][Full Text] [Related]
16. Polycyclic aromatic alkaloids. XII: In vitro- and in vivo-investigations of the cytotoxic marine alkaloid 2-bromoleptoclinidinone.
Bracher F
Pharmazie; 1997 Jan; 52(1):57-60. PubMed ID: 9035236
[TBL] [Abstract][Full Text] [Related]
17. Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31).
Satyanarayana M; Feng W; Cheng L; Liu AA; Tsai YC; Liu LF; LaVoie EJ
Bioorg Med Chem; 2008 Aug; 16(16):7824-31. PubMed ID: 18676151
[TBL] [Abstract][Full Text] [Related]
18. Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
Wang Q; Lucien E; Hashimoto A; Pais GC; Nelson DM; Song Y; Thanassi JA; Marlor CW; Thoma CL; Cheng J; Podos SD; Ou Y; Deshpande M; Pucci MJ; Buechter DD; Bradbury BJ; Wiles JA
J Med Chem; 2007 Jan; 50(2):199-210. PubMed ID: 17228862
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the discovery and development of quinolones and analogs as antitumor agents.
Xia Y; Yang ZY; Morris-Natschke SL; Lee KH
Curr Med Chem; 1999 Mar; 6(3):179-94. PubMed ID: 10219099
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification.
You QD; Li ZY; Huang CH; Yang Q; Wang XJ; Guo QL; Chen XG; He XG; Li TK; Chern JW
J Med Chem; 2009 Sep; 52(18):5649-61. PubMed ID: 19715319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
